News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharmaceutical Unit Integral To Growth Strategy: Merck KGaA (MKGAF.PK)



1/22/2014 9:25:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck KGaA (MRK) is committed to its pharmaceutical business after failing to deliver new medicines as expected, Chief Executive Officer Karl-Ludwig Kley said. New products to treat cancer should yield concrete results in the next 12 to 18 months, and the early-stage pipeline of medicines in development could pay off in three years or more, he said in an interview yesterday at the World Economic Forum in Davos, Switzerland. “The pharma business is an integral part of our strategy going forward,” said Kley, 62, who has been CEO of the family-controlled company since 2007.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES